NEW YORK (GenomeWeb News) – Clinical Genomics today said that it has licensed rights to certain cancer biomarkers from The Garvan Institute of Medical Research.
The Sydney, Australia-based firm said that it has obtained worldwide, exclusive rights to Garvan's cancer-associated methylation DNA biomarkers for the diagnosis and/or treatment of colorectal cancer. Clinical Genomics said that it will evaluate the biomarkers for possible development of diagnostic tests for early detection of colorectal cancer.
"Through this strategic licensing agreement with the Garvan Institute, we have complemented our existing technology portfolio and enhanced our ability to develop next generation products for diagnosing colorectal cancer at the earliest, most treatable stage," Lawrence LaPointe, CEO of Clinical Genomics, said in a statement.
The Garvan Institute, which also is based in Sydney, focuses on genetics research in cancer and metabolic syndromes.